Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations

Neuzillet Cindy; Gardini Andrea Casadei; Brieau Bertrand; Vivaldi Caterina; Smolenschi Cristina; Brandi Giovanni; Tougeron David; Filippi Roberto; Vienot Angelique; Silvestris Nicola; Pointet Anne-Laure; Lonardi Sara; Rousseau Benoit; Scartozzi Mario; Dahan Laetitia; Aprile Giuseppe; Boussaha Tarek; Crusz Shantini M.; Le Sourd Samuel; Meurisse Aurelia; Lievre Astrid; Vernerey Dewi; Evesque Ludovic; Heurgue Alexandra; Desrame Jerome; Lecomte Thierry; Cacheux Wulfran; Bachet Jean-Baptiste; Phelip Jean-Marc; Hautefeuille Vincent; Hammoudi Nassim; Mary Florence; Locher Christophe; Bidault-Thirot Anne; Marthey Lysiane; Touchefeu Yann; Moulin Valerie; Zaanan Aziz; Taieb Julien; Casagrande Mariaelena; Murgioni Sabina; Santini Daniele; Fornaro Lorenzo; Montagnani Francesco; Leone Francesco; Faloppi Luca; Giommoni Elisa; Lutrino Stefania Eufemia; Palloni Andrea; Brunetti Oronzo; Bergamo Francesca; Vasile Enrico; Malka David; Propper David

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations

【24h】

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations

机译：胆道癌症二线治疗的存活预测：CT2BIL群组的实现和欧洲多元验证的实现

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The benefit of second-line chemotherapy (L2) over standard first-line (L1) gemcitabine plus cisplatin (GEMCIS) or oxaliplatin (GEMOX) chemotherapy in advanced biliary tract cancer (aBTC) is unclear. Our aim was to identify and validate prognostic factors for overall survival (OS) with L2 in aBTC to guide clinical decisions in this setting.

机译：背景技术：在高级胆道癌症（ABTC）中，二线化疗（L2）上标准的第一线（L1）吉西他滨加顺铂（Gemcis）或Oxaliplatin（Gemox）化学疗法尚不清楚。我们的目的是识别和验证在ABTC中的L2的整体生存（OS）的预后因素，以指导该环境中的临床决策。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2019年第2019期|共13页
作者
Neuzillet Cindy; Gardini Andrea Casadei; Brieau Bertrand; Vivaldi Caterina; Smolenschi Cristina; Brandi Giovanni; Tougeron David; Filippi Roberto; Vienot Angelique; Silvestris Nicola; Pointet Anne-Laure; Lonardi Sara; Rousseau Benoit; Scartozzi Mario; Dahan Laetitia; Aprile Giuseppe; Boussaha Tarek; Crusz Shantini M.; Le Sourd Samuel; Meurisse Aurelia; Lievre Astrid; Vernerey Dewi; Evesque Ludovic; Heurgue Alexandra; Desrame Jerome; Lecomte Thierry; Cacheux Wulfran; Bachet Jean-Baptiste; Phelip Jean-Marc; Hautefeuille Vincent; Hammoudi Nassim; Mary Florence; Locher Christophe; Bidault-Thirot Anne; Marthey Lysiane; Touchefeu Yann; Moulin Valerie; Zaanan Aziz; Taieb Julien; Casagrande Mariaelena; Murgioni Sabina; Santini Daniele; Fornaro Lorenzo; Montagnani Francesco; Leone Francesco; Faloppi Luca; Giommoni Elisa; Lutrino Stefania Eufemia; Palloni Andrea; Brunetti Oronzo; Bergamo Francesca; Vasile Enrico; Malka David; Propper David;
展开▼
作者单位

Versailles St Quentin Univ Curie Inst Med Oncol St Cloud France;

Univ Hosp Modena Dept Med &

Surg Sci Children &

Adults Div Med Oncol Modena Italy;

Cochin Univ Hosp AP HP Gastroenterol Paris France;

Azienda Osped Univ Pisana Oncol Pisa Italy;

Gustave Roussy Inst GI Oncol Villejuif France;

St Orsola Marcello Malpighi Hosp Oncol Bologna Italy;

Univ Poitiers Hosp Jean Bernard Hosp Hepatogastroenterol Poitiers France;

IRCCS FPO Candiolo Canc Inst Med Oncol Candiolo Italy;

Besancon Univ Hosp Oncol Besancon France;

Canc Inst Giovanni Paolo II Med Oncol Unit Bari Italy;

George Pompidou European Univ Hosp AP HP Gastroenterol &

GI Oncol Paris France;

IRCCS Ist Oncol Veneto Med Oncol Unit 1 Padua Italy;

Henri Mondor Univ Hosp AP HP Med Oncol Creteil France;

Univ Cagliari Med Oncol Unit Cagliari Italy;

CHU Timone Serv Oncol Digest Pole DACCORD Radiother Digestif Anat Pathol Chirurg CISIH Oncol;

Osped San Bortolo Azienda ULSS8 Ber Dept Oncol Vicenza Italy;

Ctr Multidisciplinaire Oncol CePo Oncol Lausanne Switzerland;

Queen Mary Univ London Barts Canc Inst Oncol London England;

Ctr Eugene Marquis Gastroenterol &

Hepatol Rennes France;

Besancon Univ Hosp Methodol &

Qual Life Oncol Unit Besancon France;

Pontchaillou Univ Hosp Gastroenterol Rennes France;

Besancon Univ Hosp Methodol &

Qual Life Oncol Unit Besancon France;

Ctr Antoine Lacassagne Gastroenterol &

Hepatol Nice France;

Reims Univ Hosp Hepatol &

Digest Oncol Reims France;

Jean Mermoz Private Hosp Gastroenterol &

Hepatol Lyon France;

Tours Univ Hosp Hepatogastroenterol &

GI Oncol Tours France;

Curie Inst Med Oncol St Cloud France;

Pitie Salpetriere Univ Hosp AP HP Hepatogastroenterol &

GI Oncol Paris France;

St Etienne Univ Hosp Hepatogastroenterol &

GI Oncol St Etienne France;

Amiens Picardie Univ Hosp Hepatogastroenterol &

GI Oncol Amiens France;

St Louis Univ Hosp AP HP Paris France;

Avicenne Univ Hosp AP HP Gastroenterol Bobigny France;

Meaux Hosp Hepatogastroenterol Meaux France;

Anthony Private Hosp Antony France;

Beclere Univ Hosp AP HP Clamart France;

Nantes Univ Hosp Hepatogastroenterol &

GI Oncol Nantes France;

La Rochelle Hosp Hepatogastroenterol La Rochelle France;

George Pompidou European Univ Hosp AP HP Gastroenterol &

GI Oncol Paris France;

George Pompidou European Univ Hosp AP HP Gastroenterol &

GI Oncol Paris France;

Azienda Osped Univ Santa Maria Misericordia Dept Oncol Pisa Italy;

IRCCS Ist Oncol Veneto Med Oncol Unit 1 Padua Italy;

Univ Campus Biomed Roma Dept Med Oncol Rome Italy;

Azienda Osped Univ Pisana Unit Oncol 2 Pisa Italy;

Azienda Sanit Locale Biella Dept Oncol Ponderano Italy;

IRCCS FPO Candiolo Canc Inst Med Oncol Candiolo Italy;

Univ Hosp Oncol Cagliari Italy;

Azienda Osped Univ Careggi Florence Italy;

Antonio Perrino Hosp Dept Med Oncol Brindisi Italy;

St Orsola Marcello Malpighi Hosp Oncol Bologna Italy;

Hosp Barletta Med Oncol Unit Barletta Italy;

Azienda Osped Univ Pisana Unit Oncol 2 Pisa Italy;

Univ Torino Oncol Turin Italy;

Queen Mary Univ London Barts Canc Inst Oncol London England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Cholangiocarcinoma; Palliative chemotherapy; Prognosis; Prognostic biomarker; Stratification;

机译：胆管癌;姑息化疗;预后;预后生物标志物;分层;

相似文献

外文文献
中文文献
专利

1. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations [J] . Neuzillet Cindy, Gardini Andrea Casadei, Brieau Bertrand, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：胆道癌症二线治疗的存活预测：CT2BIL群组的实现和欧洲多元验证的实现
2. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study [J] . Matsuyama Ryusei, Morioka Daisuke, Mori Ryutaro, Cancer chemotherapy and pharmacology. . 2018,第5期

机译：用吉西滨 - 顺铂组合治疗的单机制经验作为吉西他滨-S-1组合治疗失败后不可切除的胆道癌患者的二线治疗：预期可行性研究
3. Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer [J] . Jung Jang Han, Lee Hee Seung, Jo Jung Hyun, Chemotherapy: International Journal of Experimental and Clinical Chemotherapy . 2017,第6期

机译：用Capecitabine和顺铂作为高级胆道癌的二线化疗组合治疗
4. Palliative photodynamic therapy for biliary tract carcinoma may improve survival and has a similar outcome to attempted curative surgery with positive resection margins [C] . Stephen P Pereira, W Rudiger Matull, Dipok K Dhar, World congress of the International Photodynamic Association . 2009

机译：胆道癌的姑息性光动力疗法可提高生存率，其结果与尝试切除根际阳性的根治性手术相似
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. External Validation of an Eastern Asian Nomogram for Survival Prediction After Gastric Cancer Surgery in a European Patient Cohort [O] . Daniel Reim, Alexander Novotny, Bang Wool Eom, -1

机译：在欧洲患者队列中胃癌手术后生存预测的东亚诺法图的外部验证。
7. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations [O] . Cindy Neuzillet, Andrea Casadei Gardini, Bertrand Brieau, 2019

机译：胆道癌症二线治疗的存活预测：CT2BIL队列的实现和欧洲多元验证的实现

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations

摘要

著录项

相似文献

相关主题

期刊订阅